Senesco Technologies Inc.
Formerly Nava Leisure USA, Inc.
Senesco Technologies Inc. is listed today as Eloxx Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2015 | $3 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Mar 2010 | $12 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Senesco Technologies Inc. chose not to state its revenue in its newest notice of a funding round (May 2015).
SEC Form D · May 2015
The industry group it chose in its notices: Biotechnology.
SEC Form D · May 2015
That is all the official record says: Senesco Technologies Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Senesco Technologies Inc. are on record.
Investors#
1 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Paul Edward Klaver | Person | not stated | not stated | Held preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 51 investors.
Largest shareholders today
Institutions holding Eloxx Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- Nantahala Capital Management, LLC$6 M9.91%
- EcoR1 Capital, LLC$6 M9.91%
- Aberdeen Group plc$6 M9.91%
- Samsara Biocapital, LLC$6 M9.91%
- Siren, L.L.C.$6 M9.91%
- Stonepine Capital Management, LLC$6 M9.46%
- Morgan Stanley$3 M5.02%
- Vanguard Capital Management LLC$1 M1.95%
- Geode Capital Management, LLC$0 M0.49%
- Vanguard Fiduciary Trust Co$0 M0.34%
- UBS Group AG$0 M0.05%
- Vanguard Global Advisers, LLC$0 M0.02%
- Tower Research Capital LLC (TRC)$0 M0.01%
- Wells Fargo & Company/mn$0 M0.00%
- Pioneer Family Office, LLC$0 M0.00%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Rector | Executive officer | May 2015 |
| James A. Graziano | Executive officer | May 2015 |
| Joel Brooks | Executive officer | May 2015 |
| Miguel A. de los Rios | Executive officer | May 2015 |
| Vaughn Smider | Executive officer | May 2015 |
| Jack Van Hulst | Executive officer | Apr 2010 |
| Joel P. Brooks | Executive officer | Apr 2010 |
| John E. Thompson | Executive officer | Apr 2010 |
| Richard J. Dondero | Executive officer | Apr 2010 |
| David Rector | Director | May 2015 |
| Harlan W. Waksal | Director | May 2015 |
| John W. Braca | Director | May 2015 |
| Phillip W. Frost | Director | May 2015 |
| Steven W. Rubin | Director | May 2015 |
| Vaughn Smider | Director | May 2015 |
| Christopher N. Forbes | Director | Apr 2010 |
| David C. Rector | Director | Apr 2010 |
| Jack Van Hulst | Director | Apr 2010 |
| John E. Thompson | Director | Apr 2010 |
| John N. Braca | Director | Apr 2010 |
| Rudolf C. Stalder | Director | Apr 2010 |
| Thomas C. Quick | Director | Apr 2010 |
| Warren J. Isabelle | Director | Apr 2010 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.